Literature DB >> 7001175

Hormonal and metabolic rhythms in Cushing's syndrome.

D G Johnston, K G Alberti, M Nattrass, A J Barnes, S R Bloom, G F Joplin.   

Abstract

Hormone and metabolite profiles were investigated over a 12-hr period in six patients with Cushing's syndrome, ten age- and sex-matched normal controls, and six moderately obese subjects matched for weight with the patient group. Mean diurnal plasma cortisol levels were 563 +/- 74 nmole/liter in the patients, 275 +/- 22 nmole/liter in normal controls and 241 +/- 32 nmole/liter in obese subjects, with total loss of diurnal changes in Cushing's syndrome. Fasting blood glucose concentration was similar in all groups although mild hyperglycemia occurred after meals in the Cushing's patients compared with normal and obese subjects (mean 12-hr blood glucose: Cushing's 6.31 +/- 0.39 mmole/liter; normal controls, 5.32 +/- 0.14 mmole/liter, p < 0.01; obese subjects, 5.41 +/- 0.18 mmole/liter, p < 0.05) despite marked hyperinsulinemia (mean 12-hr serum insulin: Cushing's 57.3 +/- 18.2 mU/liter; normal controls, 19.7 +/- 2.5 mU/liter, p < 0.02; obese subjects, 18.1 +/- 4.0 mU/liter, p < 0.05). Concentrations of the gluconeogenic precursors lactate, pyruvate, and alanine were raised in Cushing's syndrome, particularly postprandially. Plasma nonesterified fatty acids (NEFA), blood glycerol, and blood ketone body concentrations were comparable in all three groups although the normal diurnal variation in circulating NEFA and ketone body levels was lost in Cushing's syndrome. Serum triglyceride (TG) concentrations were grossly elevated in the Cushing's patients (mean 12-hr serum TG: Cushing's 3.51 +/- 1.23 mmole/liter; normal controls 0.89 +/- 0.19 mmole/liter, p < 0.02; obese subjects, 0.93 +/- 0.23 mmole/liter, p < 0.05) and correlated positively with serum insulin levels. Plasma glucagon concentrations were raised in Cushing's syndrome (mean 12-hr plasma glucagon: Cushing's 23.2 +/- 3.7 pmole/liter; normal controls 12.3 +/- 1.5 pmole/liter p < 0.01; obese subjects 12.2 +/0 2.0 pmole/liter, p < 0.02) and correlated positively with the serum cortisol but not with blood alanine, suggesting that some stimulatory factor other than alanine was responsible. The metabolic effects of chronic glucocorticoid excess thus may not be explained on the basis of obesity alone. Compensatory hyperinsulinemia limits the disturbance of carbohydrate and lipid metabolism in Cushing's syndrome but may be important in production of the hypertriglyceridemia observed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7001175     DOI: 10.1016/0026-0495(80)90215-2

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

Review 1.  Realising the Potential of Urine and Saliva as Diagnostic Tools in Sport and Exercise Medicine.

Authors:  Angus Lindsay; Joseph T Costello
Journal:  Sports Med       Date:  2017-01       Impact factor: 11.136

2.  Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects.

Authors:  Y T Kruszynska; M Greenstone; P D Home; N J Cooke
Journal:  Thorax       Date:  1987-11       Impact factor: 9.139

3.  Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.

Authors:  R van der Pas; C de Bruin; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M Zelissen; F H de Jong; A J van der Lely; W W de Herder; S M Webb; S W J Lamberts; L J Hofland; R A Feelders
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

4.  Regulation of ketogenesis, gluconeogenesis and the mitochondrial redox state by dexamethasone in hepatocyte monolayer cultures.

Authors:  L Agius; M H Chowdhury; K G Alberti
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

5.  Changes in the Canine Plasma Lipidome after Short- and Long-Term Excess Glucocorticoid Exposure.

Authors:  Nadja S Sieber-Ruckstuhl; Bo Burla; Susanne Spoerel; Florence Schmid; Claudio Venzin; Amaury Cazenave-Gassiot; Anne K Bendt; Federico Torta; Markus R Wenk; Felicitas S Boretti
Journal:  Sci Rep       Date:  2019-04-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.